Trial Profile
Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2022
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms PREVENE
- 28 Jun 2021 Planned primary completion date changed from 1 Feb 2021 to 22 Nov 2021.
- 19 Jun 2019 Status changed from not yet recruiting to recruiting.
- 29 Apr 2019 Planned initiation date changed from 1 Feb 2019 to 15 May 2019.